Genmab A/S (NASDAQ:GMAB) Receives $45.20 Consensus PT from Analysts

Shares of Genmab A/S (NASDAQ:GMAB) have been given an average recommendation of “Moderate Buy” by the ten research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $45.20.

A number of analysts have commented on GMAB shares. Redburn Atlantic began coverage on Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating for the company. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Wednesday, January 8th. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th.

Genmab A/S Trading Down 2.0 %

GMAB opened at $20.80 on Tuesday. The company’s 50 day moving average is $21.15 and its 200 day moving average is $24.06. The company has a market cap of $13.76 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 0.59 and a beta of 0.97. Genmab A/S has a 12-month low of $19.85 and a 12-month high of $31.88.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The business had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same quarter in the prior year, the business earned $0.47 EPS. As a group, analysts predict that Genmab A/S will post 1.28 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

Several hedge funds have recently bought and sold shares of GMAB. Bank of New York Mellon Corp increased its holdings in shares of Genmab A/S by 4.9% in the second quarter. Bank of New York Mellon Corp now owns 70,171 shares of the company’s stock worth $1,763,000 after purchasing an additional 3,283 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Genmab A/S by 7.1% during the 2nd quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock worth $470,000 after acquiring an additional 1,236 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Genmab A/S by 360.8% during the 2nd quarter. Acadian Asset Management LLC now owns 38,010 shares of the company’s stock valued at $954,000 after acquiring an additional 29,762 shares during the last quarter. Headlands Technologies LLC grew its holdings in shares of Genmab A/S by 1,702.8% in the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after purchasing an additional 4,853 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. increased its position in Genmab A/S by 26.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock worth $5,480,000 after purchasing an additional 45,376 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.